Gathering the record
Relay is organizing the evidence and source boundaries.
Adamantane-derived small molecule
Bromantane is an adamantane-derived small molecule with stimulant and anxiolytic-like pharmacology reported in older regional literature.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Bromantane is an adamantane-derived small molecule, not a peptide. Older research describes both stimulant-like and anxiety-related effects, and it is prohibited in competitive sport.
Its unusual combination of alertness-related and anxiety-related pharmacology led to human performance, brain-wave, and animal neurochemistry studies. Most clinical literature is older and regionally concentrated.
A small double-blind crossover study in healthy volunteers found prolonged brain-wave and psychostimulant signals after one exposure. Animal work supports a dopamine-synthesis hypothesis. These surrogate and mechanism findings do not establish treatment benefit, durable performance improvement, or broad safety.
Modern independent clinical effectiveness, dose-response, misuse potential, sleep effects, cardiovascular and neuropsychiatric safety, interactions, rare harms, and long-term outcomes remain uncertain. Results from small older studies may not generalize to current products or populations.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A small double-blind, placebo-controlled crossover study investigated a single bromantane exposure in healthy volunteers and measured brain-wave and performance-related effects over several hours.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Limited older human psychopharmacology and regional clinical literature; modern independent outcome evidence is sparse.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Clinical effectiveness, dose-response, misuse potential, cardiovascular and neuropsychiatric safety, and reproducibility outside older regional research.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study was small, old, and focused on surrogate psychopharmacology measures rather than a patient-important clinical outcome. It cannot establish durable benefit, misuse risk, cardiovascular safety, psychiatric safety, or effects across current products. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Small human psychopharmacology studies measured EEG and performance effects; robust modern trials for common marketed claims are not represented.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Clinical effectiveness, dose-response, misuse potential, cardiovascular and neuropsychiatric safety, and reproducibility outside older regional research.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
Bromantane is not a peptide. Human EEG and psychopharmacology studies exist, while proposed dopamine-synthesis and stress-adaptation mechanisms rely heavily on preclinical work.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Double-blind placebo-controlled crossover psychopharmacology study
Healthy volunteers
A small controlled volunteer study found prolonged EEG and psychostimulant effects.
Study administration: Not stated in the current record.
Limitations: Small, older study; surrogate effects do not establish clinical benefit.
Controlled animal neurochemical study
Rats
Endpoints were not fully described in the current record.
Animal research supported a dopamine-synthesis mechanism hypothesis.
Study administration: Not stated in the current record.
Limitations: Animal neurochemistry does not establish human therapeutic outcomes.
Safety snapshot
Modern controlled safety characterization is limited; stimulant-like, sleep, cardiovascular, neuropsychiatric, and misuse questions remain incompletely defined.
Controlled human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA-approved; historically used or registered in limited jurisdictions and prohibited in sport by WADA. Clinical effectiveness, dose-response, misuse potential, cardiovascular and neuropsychiatric safety, and reproducibility outside older regional research.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 8312546
PMID 11109517